Targeting Astrocytes for Treatment in Amyotrophic Lateral Sclerosis

Curr Pharm Des. 2017;23(33):5037-5044. doi: 10.2174/1381612823666170615110446.

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurological disorder affecting upper and lower motoneurons. The two types, sporadic and familial differ in the aetiopathogenesis but have a similar neuropathology characterized by oxidative stress, excitotoxicity and inflammation. The disease is also characterized by a non-cell autonomous mechanism with astrocytes playing a central role by affecting synaptic glutamate, the blood-brain barrier, and metabolic and trophic support. Two types of therapeutic approaches focusing on astrocytes are presented: a) emerging molecular targets (potassium inward rectifier channels and aquaporins at the astrocyte endfeet, and IP3 receptor signaling pathway), and b) cell therapy with stem cell - generated and transplanted astrocytes.

Keywords: AQP4; Blood-brain barrier; IP3 receptor pathway; Kir4.1; astrocyte; cell transplantation; endfeet; stem cells.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Amyotrophic Lateral Sclerosis / metabolism*
  • Amyotrophic Lateral Sclerosis / pathology
  • Amyotrophic Lateral Sclerosis / therapy*
  • Animals
  • Aquaporins / antagonists & inhibitors
  • Aquaporins / metabolism
  • Astrocytes / drug effects
  • Astrocytes / metabolism*
  • Astrocytes / pathology
  • Drug Delivery Systems / methods
  • Drug Delivery Systems / trends*
  • Humans
  • Potassium Channel Blockers / administration & dosage
  • Potassium Channels, Inwardly Rectifying / antagonists & inhibitors
  • Potassium Channels, Inwardly Rectifying / metabolism
  • Stem Cell Transplantation / methods
  • Stem Cell Transplantation / trends*

Substances

  • Aquaporins
  • Potassium Channel Blockers
  • Potassium Channels, Inwardly Rectifying